Moving finance upstream: A new mandate for life sciences CFOs
Learn why life sciences CFOs should move finance upstream to improve transaction readiness, decision-making, and strategic flexibility.
For growth-stage life sciences companies, financial complexity increasingly begins before a transaction is executed.
Companies are pursuing new business models, strategic collaborations, alternative sources of capital, and transactions to fund innovation and accelerate growth. These decisions can blur the lines between strategy, finance, accounting, and operations.
The implication for the Office of the CFO is clear: finance can no longer simply account for business decisions after they happen. It needs to help shape them.
Complex transactions require an integrated finance perspective
Consider two recent transactions.
AstraZeneca's 2026 collaboration with insitro included $40 million upfront and up to approximately $1.46 billion in potential milestones. Spero Therapeutics, meanwhile, entered into an approximately $105 million royalty financing tied to UTEBZI, its GSK-licensed asset.
The structures are different, but the finance challenge is similar. Headline transaction value tells only part of the story.CFOs need to understand how milestones, contractual rights and obligations, probability, timing, and alternative structures affect expected economics, liquidity, financial reporting, and ultimately the story communicated to boards and investors.
That requires an integrated perspective before terms are finalized.
-
- FP&A can model scenarios and liquidity implications.
- Valuation can inform the economics of contingent payments and financial instruments.
- Technical accounting can evaluate how the substance of an arrangement affects classification, recognition, measurement, and presentation.
The objective is not simply to get the accounting right. It is to understand how different structures affect the business before committing to them.
Finance needs a seat at the table before terms are set
There are consequences when contractual economics and financial reporting diverge. Public-company restatements have demonstrated how side agreements, return rights, contingent payment terms, and other provisions that change the substance of an arrangement can contribute to premature revenue recognition, control deficiencies, delayed filings, and significant remediation costs.
Earlier finance involvement creates an opportunity to identify these issues before they become accounting issues.
Readiness creates optionality
The same principle extends beyond individual transactions.
Life sciences M&A is gaining momentum, increasing the importance of being ready before an investor or buyer appears. Yet many companies begin preparing only when a transaction becomes imminent.
By then, important decisions about accounting policies, forecasts, controls, systems, and data have already been made.
A more effective model is continuous readiness.
That means maintaining audit-ready financial information, defensible forecasts, scalable processes and controls, and reliable clinical and operational data. For companies considering an investment or acquisition by a larger industry participant, early diligence can identify accounting, tax, operational, and data issues before buyers do.
The payoff extends beyond compliance. Readiness can accelerate diligence, reduce execution risk, strengthen management's negotiating position, and preserve strategic flexibility.
The CFO’s new mandate
For life sciences CFOs, the mandate is increasingly clear: move finance upstream.
Technical accounting, FP&A, valuation, finance operations, audit readiness, and transaction diligence need to operate as an integrated capability, before the next transaction dictates the timetable.
Related services
Our solutions are tailored to each client’s strategic business drivers, technologies, corporate structure, and culture.